| Literature DB >> 24724029 |
Caroline Jougleux-Vie1, Emeline Duhin1, Valerie Deken2, Olivier Outteryck1, Patrick Vermersch1, Hélène Zéphir1.
Abstract
Background and Purpose. Fatigue and memory impairment are common symptoms in multiple sclerosis (MS) and both may interact with cognition. This can contribute to making a complaint misrepresentative of the objective disorder. We sought to determine whether fatigue complaint in MS reflects memory impairment and investigated whether patients' subjective fatigue is associated with memory complaint. Methods. Fifty MS patients complaining of fatigue underwent subjective assessment of fatigue and memory complaint measured using self-assessment scales. Cognitive functions were assessed using a battery of neuropsychological tests, including a test of verbal episodic memory, the selective reminding test (SRT). Correlations were studied between subjective fatigue, memory complaint, and performance in verbal episodic memory. Results. Depression score, psychotropic and/or antiepileptic drug use, Expanded Disability Status Scale (EDSS) score, and MS form were confounding factors. After adjusting for these confounding factors, neither fatigue complaint nor memory complaint was correlated with SRT performance. Subjective fatigue was significantly associated with memory complaint. Conclusion. Although complaint of fatigue in MS was correlated with memory complaint, subjective fatigue was not the expression of memory impairment.Entities:
Year: 2014 PMID: 24724029 PMCID: PMC3958802 DOI: 10.1155/2014/692468
Source DB: PubMed Journal: Mult Scler Int ISSN: 2090-2654
Fatigue scale and memory complaint scale scores.
| Mean score ± SD | |
|---|---|
| FIS (French validated version) | |
| Total score (/160) | 95.4 ± 30 |
| Cognitive subscore (/40) | 22.2 ± 9.8 |
| Physical subscore (/52) | 36.4 ± 11.2 |
| Psychosocial subscore (/52) | 27 ± 10.8 |
| Social functioning subscore (/16) | 9.8 ± 4 |
| QAM score | 2.75 ± 0.84 |
FIS: Fatigue Impact Scale; QAM: Questionnaire d'Autoévaluation de la Mémoire; SD: standard deviation.
Proportion of MS patients with impaired cognitive dysfunction, assessed using BCcogSEP.
|
| |
|---|---|
| Cognitive impairment (≥4/14 scores impaired) | 22 (44) |
| SRT | 16 (32) |
| Number of words recalled | 11 (22) |
| Learning index | 11 (22) |
| Delayed recall | 11 (22) |
| 10/36 | 9 (18) |
| Total recall | 3 (6) |
| Delayed recall | 8 (16) |
| Auditory verbal spans | 23 (46) |
| Direct span | 17 (34) |
| Indirect span | 17 (34) |
| SDMT | 20 (40) |
| PASAT | 23 (46) |
| 3 sec | 20 (40) |
| 2 sec | 16 (32) |
| Crossed tapping | 10 (20) |
| GOno/GO | 6 (12) |
| Verbal fluency | 25 (50) |
| Phonemic | 22 (44) |
| Semantic | 9 (18) |
BCcogSEP: Batterie Courte d'Evaluation des fonctions Cognitives des patients ayant une Sclérose en Plaques; n: number of patients; PASAT: paced auditory serial addition test; SDMT: symbol digit modality test; SRT: selective reminding test.
Correlations between the clinical and therapeutic characteristics and the SRT, QAM, and FIS scores.
| QAM | FIS | SRT | |||||
|---|---|---|---|---|---|---|---|
| Total score | Cognitive subscore | Physical subscore | Number of words recalled | Learning index | Delayed recall | ||
| MS form | 0.80 | 0.46 | 0.49 |
| 0.12 |
|
|
| EDSS score | 0.15 |
| 0.18 |
| 0.05 |
|
|
| Concomitant treatment |
|
| 0.13 |
|
|
|
|
| BDI-II |
|
|
|
| 0.07 | 0.08 |
|
| Age | 0.63 | 0.55 | 0.81 | 0.40 | 0.54 | 0.09 | 0.73 |
| Sex | 0.43 | 0.55 | 0.31 | 0.95 | 0.1 | 0.62 | 0.35 |
| Education level | 0.56 | 0.68 | 0.67 | 0.81 | 0.18 | 0.06 | 0.11 |
| Professional activity | 0.74 | 0.54 | 0.84 | 0.40 | 0.38 | 0.07 | 0.09 |
| Other autoimmune disorders | 0.16 | 0.11 | 0.06 | 0.33 | 0.82 | 0.33 | 0.38 |
| MS treatments | 0.10 | 0.26 | 0.96 |
| 0.84 | 0.28 | 0.46 |
| Disease duration | 0.91 | 0.85 | 0.82 | 0.82 | 0.83 | 0.72 | 0.55 |
*P values < 0.05 are shown in bold; BDI-II: Beck Depression Inventory; EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact Scale; MS: multiple sclerosis; QAM: Questionnaire d'Autoévaluation de la Mémoire; SRT: Selective Reminding Test.
Clinical and demographic characteristics of MS patients.
| MS patients ( | |
|---|---|
| Females | 37 (74) |
| Males, | 13 (26 ) |
| Education level, mean years ± SD | 12 ± 2 |
| Professional activity, | 23 (46) |
| MS form, | |
| RR | 35 (70) |
| PP | 10 (20) |
| SP | 5 (10) |
| Disease duration, mean years, ± SD | 13 ± 8 |
| EDSS score, median (IQR) (25–75) | 3.0 (2.0–5.0) |
| MS treatments, | |
| No treatment | 16 (32) |
| Injectable immunomodulators | 15 (30) |
| Natalizumab | 12 (24) |
| Other immunosuppressants | 7 (14) |
| Concomitant treatments, | |
| Benzodiazepine | 11 (22) |
| Antidepressant | 12 (24) |
| Hypnotic | 1 (2) |
| Antiepileptic | 11 (22) |
| BDI-II score, median (IQR) (25–75) | 14.5 (10–26) |
| Depressive state, | |
| Minimal | 9 (18) |
| Slight | 20 (40) |
| Moderate | 10 (20) |
| High | 11 (22) |
BDI-II: Beck Depression Inventory; EDSS: Expanded Disability Status Scale; IQR: interquartile range; n: number of patients; MS: multiple sclerosis; RR: relapsing remitting; PP: primary progressive; SD: standard deviation; SP: secondary progressive.